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various clinical confounders. The area under the ROC curve 
(AUC) was 0.62 (95% confidence interval 0.50–0.73) for co-
peptin, 0.64 (0.52–0.76) for MR-proADM, 0.71 (0.61–0.82) for 
CT-proET-1, and 0.83 (0.73–0.92) for MR-proANP. The combi-
nation of MR-proANP and MR-proADM resulted in the high-
est diagnostic performance (AUC 0.88; 0.79–0.96).  Discus-
sion: Assessment of the cardiovascular plasma biomarkers 
MR-proANP and MR-proADM holds promise to support diag-
nosis of PE at triage.  © 2014 S. Karger AG, Basel 
 Introduction 
 Preeclampsia (PE) is a multi-system disorder of preg-
nancy, which is characterized by new-onset hypertension 
(systolic and diastolic blood pressures of  ≥ 140 and 90 mm 
Hg, respectively, on two occasions, at least 6 h apart) and 
proteinuria (protein excretion of  ≥ 300 mg in a 24-hour 
urine collection, or a dipstick of  ≥ 2+), that develop after 
20 weeks of gestation in previously normotensive women, 
occurs in 2–8% of pregnancies  [1] . PE may occur as a con-
sequence of an aberrant maternal inflammatory response, 
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 Abstract 
 Introduction: To investigate the ability of cardiovascular 
plasma biomarkers to identify imminent preeclampsia (PE) 
among pregnant women at triage.  Material and Methods: 
C-terminal pro-arginine vasopressin (copeptin), C-terminal 
pro-endothelin-1 (CT-proET-1), mid-regional pro-adreno-
medullin (MR-proADM), and mid-regional pro-atrial natri-
uretic peptide (MR-proANP) were prospectively measured in 
pregnant women presenting at the obstetrical triage units of 
the University Hospitals of Basel and Zurich, Switzerland. Lo-
gistic regression and receiver operating characteristics (ROC) 
analysis was used to assess and quantify the predictive abil-
ity of cardiovascular biomarkers.  Results: Of the 147 includ-
ed women, 27 (18.4%) were diagnosed at admission with PE. 
All biomarker levels were significantly higher in participants 
with PE as compared to controls. However, only MR-proANP, 
MR-proADM and CT-proET-1 were significant and indepen-
dent predictors of PE, after taking into account the effect of 
 Received: September 24, 2013 
 Accepted after revision: February 28, 2014 
 Published online: May 17, 2014 
 Dr. Olav Lapaire 
 Department of Obstetrics and Gynecology 
 University Hospital Basel 
 Spitalstrasse 21, CH–4031 Basel (Switzerland) 
 E-Mail olapaire   @   uhbs.ch 
 © 2014 S. Karger AG, Basel
1015–3837/14/0363–0202$39.50/0 
 www.karger.com/fdt 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
14
4.
20
0.
17
.3
8 
- 1
2/
29
/2
01
4 
1:
30
:2
5 
PM
 Cardiovascular Biomarkers in 
Preeclampsia 
Fetal Diagn Ther 2014;36:202–207
DOI: 10.1159/000361016
203
including a systemic vascular dysfunction. The inflam-
matory reaction may lead to oxidative stress. Further-
more, oxidative stress can stimulate an inflammatory re-
sponse, forming the platform for a positive feedback be-
tween the two conditions  [2] . However, whereas blood 
biomarkers of angiogenesis are good predictors of PE  [3, 
4] , mediators of inflammation, namely cytokines, do not 
indicate development of PE  [5] .
 According to the latest report of Confidential En-
quires into Maternal Deaths in the United Kingdom, the 
most common reason for maternal death resulting from 
substandard care was a failure to appropriately diagnose 
or manage PE  [6] . Although maternal deaths resulting 
from PE are rare events, most of the deaths were found 
to be associated with substandard care, caused by a fail-
ure to recognize the signs and symptoms of this condi-
tion  [7] .
 The standard methods to diagnose PE consist of stan-
dardized blood pressure measurement, urine analysis for 
the detection of proteinuria and the determination of uric 
acid, platelet counts and liver enzymes in the maternal 
blood  [8] . However, the diagnostic performance of these 
parameters is still controversial, and they are poor predic-
tors of either maternal or fetal complications  [9] . There-
fore, a reliable new diagnostic test may facilitate clini-
cian’s assessment, clinical decision and the correct iden-
tification of high-risk pregnancies at admission.
 Copeptin is a stable by-product of the arginine vaso-
pressin (AVP) synthesis and has become a widely used 
surrogate marker of AVP release, reflecting hemody-
namic and osmoregulatory effects, as well as individual 
stress levels  [10] . Endothelin-1 (ET-1), a potent vasocon-
strictor, is secreted by endothelial cells in response to var-
ious stressors, and its secretion can be reliably estimated 
by measuring the carboxy-terminal portion of the ET-1 
precursor (CT-proET-1)  [11] . The atrial natriuretic pep-
tide (ANP) is released into circulation with its stable by-
product mid-regional pro-ANP (MR-proANP), a bio-
marker for cardiovascular hemodynamic stress and hy-
pertension  [12] . Adrenomedullin (ADM) and its stable 
by-product mid-regional pro-ADM (MR-proADM) are 
expressed in all organs but predominantly in vascular en-
dothelial cells and vascular smooth muscle cells where it 
regulates circulation and endothelial permeability  [13, 
14] .
 In this cross-sectional prospective study, we investi-
gated the validity of these promising biomarkers, namely 
copeptin, MR-proANP, CT-proET-1, and MR-proADM 
to accurately discriminate preeclamptic patients versus 
controls at triage.
 Materials and Methods 
 This study included 147 pregnant women between 24 and 42 
weeks of gestation in a prospective, cross-sectional study per-
formed between March 2009 and July 2010 at the University Hos-
pitals of Basel and Zurich, Switzerland. Women were eligible either 
if they presented or were referred to the obstetrical triage unit of 
both centers, for example with clinical symptoms of suspected PE 
or with increased risk of preterm delivery. All patients provided 
written informed consent.
 Exclusion criteria were: (1) patients in the first and second stage 
of labor and with regular uterine contractions, (2) pregnant wom-
en with preexisting hypertension before 20 weeks of gestation, (3) 
diabetes mellitus, (4) kidney and heart disease, (5) signs of chorio-
amnionitis, and (6) confirmed PE before admission.
 The study was approved by the institutional review boards of 
the University Hospital of Basel and Zürich (Ethikkommission 
beider Basel, EKBB 07/09, Kantonale Ethikkommission Zürich, 
KEK 08/09) and was carried out according to the principles of the 
Declaration of Helsinki. Written informed consent was obtained 
from all participating patients.
 Characteristics from mothers and infants were collected from 
the charts. In detail, from mothers: age at delivery and body mass 
index (BMI) before pregnancy; in pregnancy parity, singleton or 
twin pregnancy, gestational diabetes mellitus (GDM), and admin-
istration of any antenatal steroids for fetal lung maturation; at de-
livery umbilical cord artery pH. From infants: gestational age 
(GA), based on the ultrasonographical crown-rump length mea-
surement at the end of the first trimester, birth weight, and Apgar 
scores at 5 and 10 min of life. Diagnosis of PE was subsequently 
established in the obstetrical triage unit of both centers, according 
to the definition of elevated blood pressure ( ≥ 140 mm Hg systolic 
and  ≥ 90 mm Hg diastolic blood pressure) and significant protein-
uria ( ≥ 300 mg/24 h, or  ≥ ++ in urine dipsticks). Additional param-
eters, such as hemolysis, thrombocytopenia, elevated liver en-
zymes, and/or severe intrauterine growth restriction and fetal 
compromise were recorded. GDM was diagnosed using a 75-gram 
oral glucose tolerance test in the second trimester.
 After collecting blood in EDTA tubes, samples were centri-
fuged and plasma was frozen at –28  °  C. Each pro-peptide was mea-
sured in a single batch. MR-proANP (pmol/l), CT-proET1 
(pmol/l), and MR-proADM (nmol/l) were measured by means of 
fully automated BRAHMS KRYPTOR immunofluorescent assays 
(B·R·A·H·M·S GmbH, part of Thermo Fisher Scientific, Hennigs-
dorf, Germany) and Copeptin (pmol/l) was measured with a re-
search sandwich immunoluminometric assay (BRAHMS C-termi-
nal pro-AVP luminescence immunoassay, BRAHMS) as described 
previously  [15] .
 Continuous variables were presented as medians with range 
whereas categorical variables as number of cases with rates. Be-
tween-group comparisons were performed using the Mann-Whit-
ney U test, χ 2 test, and Fisher’s exact test, as appropriate. The effect 
of various clinical parameters on biomarkers levels was assessed by 
linear regression analysis after logarithmic transformation of the 
dependent variable. Simple and multivariable linear regression 
models were used to explore the unadjusted and adjusted effect of 
these parameters, respectively. According to good common prac-
tice, we used the term multivariable analysis as various input vari-
ables, but only one outcome parameter each time was analyzed. 
Multivariable logistic regression analysis was used to explore the 
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diagnostic value of each biomarker separately after taking into ac-
count the effect of possible clinical confounders (nullipara, single-
ton pregnancy, GDM, antenatal steroids, maternal age at delivery, 
GA at delivery). The combined effect of all biomarkers was also 
assessed in a separate model. Receiver operating characteristic 
(ROC) curves were constructed and the area under the curve 
(AUC) was calculated in order to quantify the diagnostic ability of 
each biomarkers. A combined biomarker index consisting of the 
product between MR-proANP and MR-proADM, was also evalu-
ated. A p value <0.05 was considered to be significant in all in-
stances. Statistical analysis was performed with IBM SPSS version 
20.0 (IBM Corp., Armonk, N.Y., USA).
 Results 
 A total of 147 women with complete clinical and bio-
marker data were included in the analysis. Demographic 
characteristics and pregnancy outcomes are presented in 
 table 1 . Women in the PE group were enrolled on average 
4.2 weeks earlier in pregnancy (mean 32.84 weeks GA, 95% 
CI 31.35–34.32) as compared to controls (mean 37.06 weeks 
GA, 95% CI 36.39–37.73), p < 0.001. Enrollment was done 
at the time point of blood sampling and was done on aver-
age 25 h before delivery (95% CI 19–32 h); in women with 
PE, blood sampling was 7.8 h closer to delivery (on average 
18.9 h before delivery, 95% CI 8.8–29.1) than in controls 
(26.8, 95% CI 19.3–34.2) without a significant difference.
 MR-proANP, MR-proADM, and CT-proET1 levels 
were significantly higher in women with PE as compared 
to controls, whereas the between-group difference in co-
peptin levels was marginal ( table 1 ). 
 The effect of various clinical parameters on the study 
biomarkers is analyzed in  table 2 . PE was a significant and 
independent determinant of higher MR-proANP, MR-
proADM, and CT-proET1 levels. Increased MR-proANP 
was also independently related to the administration of 
antenatal steroids, whereas increased MR-proADM was 
associated with multiple gestation and larger GA. Lower 
GA and lack of antenatal steroids were the only signifi-
cant determinants of increased copeptin levels ( table 2 ).
 Logistic regression analysis revealed that MR- proANP, 
MR-proADM, and CT-proET1 were significant and in-
dependent predictors of PE ( table 3 ). When all four bio-
markers were included in a separate model, only MR-pro-
ANP and MR-proADM showed a significant association 
with PE ( table 3 ).
 MR-proANP presented the higher diagnostic perfor-
mance (AUC 0.83; 95% CI 0.73–0.92), followed by CT-
proET-1 (AUC 0.71; 95% CI 0.61–0.82), MR-proADM 
(AUC 0.64; 95% CI 0.52–0.76), and copeptin (AUC 0.62; 
95% CI 0.50–0.73) ( fig. 1 ). Since MR-proANP and MR-
proADM were related to PE independently of each other 
( table 3 ), the two biomarkers were combined (product of 
values). That biomarker index presented the highest di-
agnostic performance (AUC 0.88; 95% CI 0.79–0.96), al-
beit without statistically significant difference compared 
to MR-proANP alone (p = 0.176).
 Discussion 
 In this prospective cross-sectional study, we analyzed 
quantitatively various promising plasma biomarkers of 
vasoactive peptides, namely copeptin, MR-proANP, CT-
proET1, and MR-proADM in pregnant women at admis-
sion. The major finding is that by combining the two bio-
markers MR-proADM and MR-proANP, a high diagnos-
tic accuracy is achieved in specifically discriminating 
pregnant women with PE from controls at triage.
 The results of this current study have important clini-
cal implications, because the proposed marker combina-
 Table 1.  Characteristics of the study groups
PE
(n = 27)
Controls
(n = 120)
p
Maternal characteristics
BMI before pregnancy 23 (20/29) 22 (19/28) NS
Nullipara 24 (89) 66 (55) <0.001
Singleton 21 (78) 102 (85) NS
Gestational diabetes
mellitus 0 (0) 6 (5) NS
Antenatal steroids (any) 17 (63) 29 (24) <0.001
Age at delivery, years 36 (25/41) 32 (25/39) 0.034
GA at delivery, weeks 34 (27/37) 38 (32/41) <0.001
Delivery vaginal 1 (4) 28 (48) <0.001
Infants characteristics
Male/female 16/11 (60/40) 71/49 (60/40) NS
Birth weight, kg 1.7 (0.6/2.7) 3.0 (1.6/3.8) <0.001
Small for GA 10 (37) 16 (13) 0.009
pH arterial umbilical cord 7.30 (7.2/7.4) 7.29 (7.2/7.4) NS
Apgar 5 min 8 (6/9) 9 (8/10) <0.001
Biomarkers at triage
Copeptin, pmol/l 7.0 (2.0/42.0) 4.9 (2.1/14.7) 0.046
MR-proANP, pmol/l 157 (51/334) 67 (36/136) <0.001
CT-proET-1, pmol/l 71 (49/101) 57 (41/85) <0.001
MR-proADM, nmol/l 1.4 (0.7/2.3) 1.1 (0.5/1.9) 0.010
 Data expressed as median (10th–90th percentile range) or num-
ber of cases (%). Statistical significance was assessed by Mann-Whit-
ney U test, χ2 test or Fisher’s exact test, as appropriate. NS = Not 
significant (p ≥ 0.05).
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tion may allow a fast and easy-to-implement identifica-
tion of patients at risk for PE at triage and therefore may 
have the potential to reduce unnecessary admissions with 
increased monitoring, as well as lowering the number of 
misdiagnosed or unrecognized patients at admission, 
that may lead to severe maternal/fetal morbidity and 
mortality  [6, 7] . Furthermore, the marker combination 
may help to reduce the number of inappropriate dis-
charges as well as iatrogenic preterm deliveries.
 Several markers have the promising perspective to be 
implemented in future clinical assessment of patients at 
risk for PE. Among them, blood biomarkers of angiogen-
esis are currently at the most advanced state of develop-
ment  [3, 4] . Using the sFlt-1/PlGF ratio to diagnose PE, 
Verlohren et al.  [16] demonstrated a high sensitivity and 
specificity with an AUC for all types of PE of 0.95 and for 
early-onset PE of 0.97. Whereas the predictive value for 
subsequent adverse outcomes in women admitted with 
suspected PE before 34 weeks’ GA was found to be respect-
able when based on maternal arterial hypertension and 
proteinuria alone (AUC 0.84), it was significantly improved 
when the sFlt1/PlGF ratio was added (AUC 0.93)  [17] .
 Compared to the AUCs found for the sFlt/PlGF ratio 
(ranging from 0.93 to 0.97) in identifying PE in suspect-
ed pregnant women, our here presented marker combi-
nation of plasma MR-proADM and MR-proANP dis-
 Table 2.  Dependencies of plasma biomarkers levels
 Copeptin CT-proET-1 MR-proANP MR-proADM
un adjusted adjusted unadjusted adjusted unadjusted adjusted unadjusted adjusted
Nullipara 0.163‡ 0.037 0.183 0.154 0.189‡ 0.061 –0.024 –0.188
Singleton –0.101 –0.067 –0.123 –0.027 –0.128 0.004 –0.139 –0.224†
Preeclampsia 0.187‡ 0.125 0.272† 0.220‡ 0.455* 0.269† 0.217† 0.363*
Gestational diabetes mellitus –0.098 –0.032 0.036 0.096 –0.136 –0.042 0.122 0.130
Antenatal steroids 0.069 –0.388† 0.195‡ 0.135 0.466* 0.277‡ –0.078 0.146
Maternal age at delivery –0.088 –0.159 0.083 0.083 0.184‡ 0.091 0.102 0.077
GA at delivery –0.271† –0.513* –0.151 0.062 –0.456* –0.104 0.203‡ 0.479*
BMI before pregnancy –0.077 –0.088 0.027 0.026 –0.023 –0.032 –0.099 –0.131
 Data are adjusted regression coefficients obtained from simple linear regression models (unadjusted effect) and multivariable linear 
regression analysis (effect of each factor adjusted for the effect of the others). Biomarker levels are log-transformed. * p < 0.001; † p < 
0.01; ‡ p < 0.05.
 Table 3.  Value of study biomarkers in diagnosing PE
Model 1:
copeptin
Model 2:
CT-proET-1
Model 3:
MR-proANP
Model 4:
MR-proADM
Model 5:
biomarkers only
Nullipara 0.013 NS 0.024 0.017 –
Singleton NS NS NS NS –
Gestational diabetes mellitus NS NS NS NS –
Antenatal steroids NS NS NS NS –
Maternal age at delivery NS NS NS NS –
GA at delivery NS NS NS 0.013 –
BMI before pregnancy NS NS NS NS –
Copeptin NS – – – NS
CT-proET-1 – 0.022 – – NS
MR-proANP – – 0.013 – <0.001
MR-proADM – – – 0.002 0.012
 Multivariable logistic regression analysis for assessing the diagnostic value of biomarkers after taking into account clinical confound-
ers. The dependent variable in all models is PE. Data represent levels of significance (p values). NS = Not significant (p ≥ 0.05).
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plays a similar AUC with 0.88 (95% CI 0.79–0.96). A 
recently published study found high sensitivity and spec-
ificity for MR-proANP alone with AUC of 0.85 (95% CI 
0.79–0.90) in the discrimination of patients with PE ver-
sus controls close to delivery  [18] which is in line with 
our findings of an AUC for MR-proANP alone of 0.83 
(95% CI 0.73–0.92). The authors showed 3-fold elevated 
MR-proANP level in patients with PE as compared to 
normotensive controls, pointing towards high cardio-
vascular hemodynamic stress in PE, corroborating our 
data of more than 2-fold higher MR-proANP level in the 
preeclamptic group  [18] . Accordingly, the degree of ar-
terial hypertension has been found to be mirrored by 
plasma MR-proANP level in non-pregnant subjects  [12, 
19] .
 Apart from the hypertension marker MR-proANP, 
only MR-proADM increased the sensitivity and specific-
ity in discriminating preeclamptic from control patients 
when combined with MR-proANP. Copeptin and CT-
proET-1 did not contribute any added value in our mod-
el. So far, copeptin was investigated in just one study with 
PE and copeptin levels were found to increase markedly 
in parallel with the severity of PE when compared to 
women with normal, ongoing pregnancies of similar GAs 
in the third trimester  [20] . In our study copeptin levels 
were also higher in the preeclamptic group (1.5-fold) but 
PE was not an independent determinant of higher co-
peptin in multivariable regression analysis.
 In our study, the incidence of PE (18%) was higher as 
compared to about 5% in the overall population  [1] . This 
is explained by the following two factors: (1) the ratio of 
high-risk pregnancies is usually higher at university hos-
pitals, especially in the triage unit, as compared to the 
overall distribution, and (2) one important exclusion cri-
terion of our study was regular uterine contractions dur-
ing the first and second stage of labor. Hence, pregnant 
women presenting with commenced physiological labor 
were not included.
 A limitation of our study was the time point of blood 
sampling in relation to the progress of PE. Furthermore, 
due to the cross-sectional design and enrollment of wom-
en at admission to the triage unit in order to establish di-
agnosis, the severity of PE varied. Therefore, additional 
trials are needed to prospectively investigate these mark-
ers in the second and third trimester of pregnancy up to 
the onset of manifest PE to assess the predictive value of 
these markers.
 In summary, the current study shows that the combi-
nation of MR-proADM and MR-proANP might be a 
promising tool for risk stratification of pregnant women 
undergoing PE evaluation at triage. Whether both cardio-
vascular markers may help to identify pregnant women 
at risk for PE at early stage and whether both cardiovas-
cular markers may add diagnostic information to the 
well-established angiogenesis biomarkers warrants fur-
ther studies. On the whole, biomarker-assisted screening 
for PE appears to be a promising instrument in cost re-
duction  [21] .
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 Fig. 1. ROC curves at triage for the diagnosis of PE of plasma bio-
markers as indicated. 
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